Publication: Deflazacort vs prednisone treatment for Duchenne muscular dystrophy (DMD): A meta-analysis of disease progression rates in recent multicenter clinical trials
This clinical research article, published in the Muscle & Nerve Journal, compares disease progression among boys enrolled in the placebo arms of 2 DMD clinical trials receiving deflazacort or prednisone/prednisolone
Review the outcomes of a post hoc meta-analysis of deflazacort and prednisone in DMD patients receiving placebo in 2 independent phase 3 trials
The primary functional outcomes reflecting measures of disease progression over 48 weeks are discussed
McDonald CM, Sajeev G, Yao Z, et al. Muscle Nerve. 2020;61:26–35
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0311 | June 2021
Sign in or register to access exclusive content on this site